{"anticipatedPostingDate":"2027-12","denomUnitsSelected":"Participants","description":"An adverse event of special interest (AESI) were any serious or nonserious AE that were of scientific or medical concern as defined by the sponsor and specific to the program, for which ongoing monitoring and rapid communication to the sponsor were appropriate. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment (tucatinib, trastuzumab or fulvestrant). AESIs for this study were related to hepatoxicity.","reportingStatus":"NOT_POSTED","timeFrame":"From first dose of the study treatment (Day 1) up to the last dose of study treatment (approximately 52.7 months)","title":"Number of Participants With TEAEs of Special Interest","type":"SECONDARY"}